Zim Laboratories Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/4yru5j51i1e3ea6gkbvljg4o.pdf

Key Takeaways


The Pivot: NIP/OTF Growth vs. Margin Reality

Anwar Daud: "The company is in the stage of a pivot."

Regulatory Pipeline & Commercial Launch Timeline

Anwar Daud: "In the next 2 years... do you see the company growing? And we said, yes, certainly, because all the MAs are coming in now and coming in the 3 or 4 quarters that we have spoken about."

Legacy Business: The Deliberate Reset


Capacity, CapEx & the Balance Sheet

Anwar Daud: "We are building in CapEx for the future. We know that the products we have developed have potential. We have had early successes in the MAs... our filing strategy is in place, and our partnerships are in place as well."

Geographic & Partnership Expansion

Anwar Daud: "The out-licensing deals are with companies in the size of between $350 million to about $1.5 billion. And they will not sign these agreements unless they are confident of the product as well as the quality of the dossier and the quality of the submission."

R&D & the Next Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
Legacy business stabilizationRecover to previous levels, nominal growth of 5–10%FY26; more confident numbers at end of Q2 FY26
NIP/OTF revenue contribution30–40% of total sales"Coming years"
NIP/OTF revenue contributionUp to 50% of total business"Over a period of time"
EBITDA marginUpper teens"Going forward"
Revenue growth25–30%Next 2–3 years, contingent on MAs arriving over next 3–4 quarters
First sales from new productsStarting to sellBy Q3 FY26
Commercial launches3 launchesH2 FY27
Neuraxpharm product launchLaunchIn another 2 quarters
Dimethyl Fumarate and Buprenorphine revenueRevenue from regulated marketsBy end of Q3 and Q4 FY26
Remaining NIP pipeline filings4 products finalized and filedThrough FY26
Quantitative guidance on NIP/OTF percentage and revenueExact guidance providedAfter Q2 FY26, once clarity on MAs and marketing partner agreements is available
Australia launch clarityClear idea of launchBy Q2 or Q3 FY26
CapExNo further major projects; only upgradesOngoing
R&D spend~8.5% of revenue on similar absolute numbersGoing forward

Key Metrics

MetricQ4 FY25
Total Operating Income₹108.7 crore, +12.9% QoQ and -7.7% YoY
EBITDA₹16.3 crore, +22.5% QoQ and -5.2% YoY
EBITDA margin15%, improved from 12.7% in FY24
PAT₹4.9 crore, +22.1% QoQ and -39.7% YoY
PAT margin4.5%
Pharmaceutical business revenue₹89.1 crore, 82% of total operating income, +20.6% QoQ and -8.8% YoY
Nutraceutical business revenue₹19.6 crore, 18% of total operating income
R&D investment₹7.6 crore, 7% of total operating income
CapEx₹6.5 crore, primarily directed towards infrastructure upgrades and specialized facility enhancement
Total Operating Income (FY25)₹379 crore, +3.2% YoY
EBITDA (FY25)₹49.5 crore, +6.4% YoY
EBITDA margin (FY25)13.1%
PAT (FY25)₹12.2 crore, PAT margin of 3.2%
NIP + OTF sales (FY25)₹62.4 crore, 16.5% of total revenue, grew 64% YoY
NIP segment contribution (FY25)₹43.7 crore
OTF contribution (FY25)₹18.6 crore
Export market contribution (FY25)₹312.5 crore, 83% of total operating income
Domestic market contribution (FY25)₹66.5 crore, 17% of total operating income
Annual CapEx (FY25)₹36.5 crore
R&D spend (FY25)8.8% of total operating income
NIP filings (FY25)23 filings for 6 molecules
OTF filings (FY25)17 filings for 5 molecules
Cumulative EU NIP filings to date7
NIP pipeline12 products, development of 8 completed
Inventory days80–81 days, currently on a 100-day cycle, improving to 90 days
Net GCA days60–63 days
Domestic revenue FY24 vs FY25₹64.6 crore in FY24, ₹53.6 crore in FY25, a 17% de-growth
Government of Maharashtra order not received in FY25~₹20 crore order deferred due to election year
Employee cost expectation FY26₹65–68 crore, expected to stabilize
Legacy business growth expectation FY265%–10%
NIP + OTF contribution to total sales expectation30%–40% going forward